Scholar Rock/$SRRK

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Scholar Rock

Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.

Ticker

$SRRK

Sector

Health Care
Primary listing
NASDAQ

Employees

128
Headquarters
Cambridge, United States
Website
www.scholarrock.com

Scholar Rock Metrics

BasicAdvanced
$3.3B
-
-$2.80
-
-

What the Analysts think about Scholar Rock

Analyst ratings (Buy, Hold, Sell) for Scholar Rock stock.

Bulls say / Bears say

Scholar Rock's lead product, Apitegromab, is in Phase 3 clinical trials for treating spinal muscular atrophy, indicating potential for significant market impact upon approval. (directorstalkinterviews.com)
Analysts have set an average 12-month price target of $42.17 for SRRK, suggesting a 23.16% upside from the current price, reflecting strong confidence in the company's growth prospects. (stockanalysis.com)
The company's proprietary platform targeting the TGFβ superfamily positions it uniquely in developing therapies for serious diseases, potentially leading to breakthroughs in multiple treatment areas. (directorstalkinterviews.com)
Scholar Rock reported a net loss of $264.16 million in the trailing twelve months, highlighting ongoing financial challenges typical of pre-revenue biotech firms. (stockanalysis.com)
The company's Price-to-Book ratio of 8.8x is significantly higher than the industry average of 1.6x, suggesting potential overvaluation relative to its peers. (simplywall.st)
With a negative free cash flow of $134.3 million, Scholar Rock faces financial strain that could impact its ability to fund ongoing research and development without additional capital. (directorstalkinterviews.com)
Data summarised monthly by Lightyear AI. Last updated on 12 Jul 2025.

Scholar Rock Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Scholar Rock Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

Scholar Rock News

AllArticlesVideos
Scholar Rock to Host Conference Call to Discuss Second Quarter 2025 Financial Results and Provide Business Update on August 6, 2025

Scholar Rock to Host Conference Call to Discuss Second Quarter 2025 Financial Results and Provide Business Update on August 6, 2025

Business Wire·3 weeks ago
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire·3 weeks ago
Scholar Rock CEO on its drug that could preserve muscle in weight-loss drug users

Scholar Rock CEO on its drug that could preserve muscle in weight-loss drug users

CNBC Television·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $SRRK

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events
FAQs